Entera Bio (NASDAQ:ENTX – Get Free Report) is expected to announce its Q4 2025 results before the market opens on Friday, March 27th. Analysts expect the company to announce earnings of ($0.09) per share for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Monday, March 23, 2026 at 6:30 AM ET.
Entera Bio Stock Down 11.2%
Entera Bio stock opened at $1.19 on Friday. The business has a 50 day moving average price of $1.43 and a two-hundred day moving average price of $1.93. Entera Bio has a 12 month low of $1.00 and a 12 month high of $3.22. The stock has a market cap of $54.57 million, a price-to-earnings ratio of -4.76 and a beta of 1.83.
Analyst Upgrades and Downgrades
Several brokerages have recently weighed in on ENTX. Weiss Ratings reissued a “sell (d-)” rating on shares of Entera Bio in a report on Thursday, January 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Entera Bio in a research report on Monday, February 9th. Finally, Wall Street Zen upgraded shares of Entera Bio to a “sell” rating in a research note on Saturday, December 27th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Entera Bio has a consensus rating of “Hold” and a consensus target price of $10.00.
Insider Transactions at Entera Bio
In other Entera Bio news, Director Geno J. Germano purchased 20,000 shares of the business’s stock in a transaction on Monday, March 9th. The stock was purchased at an average price of $1.30 per share, for a total transaction of $26,000.00. Following the completion of the purchase, the director directly owned 40,000 shares in the company, valued at approximately $52,000. This trade represents a 100.00% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have bought a total of 69,000 shares of company stock valued at $92,530 over the last three months. Corporate insiders own 10.38% of the company’s stock.
Institutional Investors Weigh In On Entera Bio
Several large investors have recently modified their holdings of the stock. Jane Street Group LLC grew its position in Entera Bio by 142.6% in the fourth quarter. Jane Street Group LLC now owns 74,064 shares of the company’s stock valued at $144,000 after acquiring an additional 43,536 shares during the period. Schonfeld Strategic Advisors LLC lifted its holdings in shares of Entera Bio by 5.2% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 596,585 shares of the company’s stock valued at $1,157,000 after acquiring an additional 29,629 shares during the period. Citadel Advisors LLC boosted its stake in shares of Entera Bio by 243.0% in the 3rd quarter. Citadel Advisors LLC now owns 39,978 shares of the company’s stock valued at $77,000 after purchasing an additional 28,322 shares in the last quarter. HighTower Advisors LLC boosted its stake in shares of Entera Bio by 137.8% in the 4th quarter. HighTower Advisors LLC now owns 43,140 shares of the company’s stock valued at $84,000 after purchasing an additional 25,000 shares in the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of Entera Bio by 22.2% in the 4th quarter. Renaissance Technologies LLC now owns 108,001 shares of the company’s stock worth $210,000 after purchasing an additional 19,601 shares during the last quarter. 14.11% of the stock is currently owned by institutional investors.
Entera Bio Company Profile
Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.
The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.
See Also
Receive News & Ratings for Entera Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entera Bio and related companies with MarketBeat.com's FREE daily email newsletter.
